Press Release • May 03, 2017 07:13 CEST
Superstartup of the Year (2016) Ulf Skarin, The Week’s Stores, Mikael Karlsson, Almi Invest, Charles Walther, Bibb Instruments, Maria Kesslling, Almi Invest and PO Lindsten, Weekly Stores.
 

Almi Invest invests just under SEK 1 million in B! BB Instruments, a company in Lund that develops an instrument that enables quick and easy testing of suspected cancer patients. The issue of a total of SEK 4.6 million also includes Swedish Growth Fund, Christer Fåhraeus via Fårö Capital and a number of private and institutional investors. The money will go for launch of the company’s first product in the Nordic market. 

B! BB develops EndoDrill, an instrument that facilitates the diagnosis of cancer tumors by drilling into the tissue. This makes it possible to reach deep-lying tumors. This differs from today’s methods that are difficult to capture deeply lying tissue. 

The first version of EndoDrill is used to take samples in the stomach, where tumors are difficult to diagnose with today’s methods. Today, repeated samples must be taken or waived until the tumor has grown in size, causing unnecessary suffering to the patient. Often surgery is required to make a final diagnosis. With EndoDrill, you can easily set an early and safe diagnosis, which allows the patient to get the right treatment faster. 

EndoDrill has the potential to become a new standard method for sampling in deep-lying tumors, says Per Antonsson, Investment Manager at Almi Invest. This would save a lot of money for healthcare as you can reduce the number of tests and avoid unnecessary operations. 

B! BB already has orders for EndoDrill from several hospitals in Sweden and deliveries of sterile disposable instruments are scheduled for 2017. The company was named 2016 for the Superstartup of the Year by Almi Invest in cooperation with Veckans Affärer. 

https://www.va.se/nyheter/2016/05/10/arets-superentreprenor/ 

Financing enables the launch of EndoDrill and continued development of other closely related biopsy instruments for major indications, such as lung, intestinal, prostate and breast cancer. Our vision is to improve diagnostics for many of the most common forms of cancer, and we see a significant market potential in this, says Fredrik Lindblad, CEO B! BB Instruments. 

For further information, please contact: 

Per Antonsson, Investment Manager Almi Invest, tel 070 872 87 17, mail per.antonsson@almiinvest.se
Fredrik Lindblad, CEO B! BB, tel 0708-999 486, mail fredrik.lindblad@bibbinstruments.com
Maria Kessling, Communications Manager Almi Invest, tel. 076-880 88 10, mail maria.kessling@almiinvest.se
 

About Almi Invest 

Almi Invest is Sweden’s most active investor in startups. We make investments throughout the country through 8 regional venture capital companies and a national venture capital company in GreenTech. Almi Invest manages approximately SEK 3 billion and has since invested approximately 600 startups. Our best holdings have been acquired by Google, Microsoft, Qlik and Apple, for example, or listed on different stock exchanges. Almi Invest is a venture capital company within the Almi Group.

Categories: News

Tags:

About the Author